![]() An article for Bloomberg Law touches on a new report from the Partnership for Part D Access which demonstrates that Medicare Part D plans are successfully using tools to push patients toward less expensive drugs under the six protected classes policy. The article notes that the study, conducted by Avalere Health, shows drug plans are tools such as requiring copays for brand drugs in the protected classes to control patient costs and promote access to cost-effective treatments. The piece amplifies the concerns of patient advocates in response to proposed changes from the Administration. “Making changes to the policy because of cost is reckless,” said Chad Worz of the American Society of Consultant Pharmacists. “It’s not something you play with to get a cheaper drug.”
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. Archives
September 2022
Categories |
Learn more |
What's New? |
|